Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

John Wells

Hematology & Oncology Fort Smith, AR Medical Doctor

NPI 1174532469 CMS profile 766845

7301 Rogers Ave, Fort Smith, AR 72903

Open in the dashboard

General payments

$5,148

313 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, John Wells of Fort Smith, AR is reported in the CMS Open Payments database as having received $5,148 across 313 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $925 55
2021 General $1,133 69
2020 General $1,343 85
2019 General $1,747 104

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Wells
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to John Wells were reported at $0. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year John Wells Hematology & Oncology median Middle half National median
2019 $1,747 $529 $121–$2,516 $163
2020 $1,343 $339 $82–$2,213 $114
2021 $1,133 $263 $49–$1,965 $132
2022 $925 $416 $103–$2,395 $149
2023 $0 $542 $125–$2,646 $160
2024 $0 $692 $141–$3,008 $164
2025 $0 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Merck Sharp & Dohme Corporation $732 45 payments
  2. Amgen Inc. $669 38 payments
  3. AstraZeneca Pharmaceuticals LP $406 26 payments
  4. E.R. Squibb & Sons, L.L.C. $333 28 payments
  5. Eisai Inc. $273 15 payments
  6. Rigel Pharmaceuticals, Inc. $239 13 payments
  7. BeiGene USA, Inc. $233 17 payments
  8. Celgene Corporation $213 14 payments
  9. Regeneron Healthcare Solutions, Inc. $201 9 payments
  10. Novartis Pharmaceuticals Corporation $188 11 payments
  11. Other $1,661 97 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $5,079 312 payments
  2. Education $69 1 payment
Products named General payments · program years 2019–2022
  1. KEYTRUDA $643 38 payments
  2. LIBTAYO $337 16 payments
  3. XGEVA $289 15 payments
  4. Lenvima $273 15 payments
  5. OPDIVO $251 22 payments
  6. Nplate $240 12 payments
  7. Tavalisse $239 13 payments
  8. BRUKINSA $233 17 payments
  9. LYNPARZA $184 13 payments
  10. Udenyca $163 10 payments
  11. Other $3,540 213 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

313 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record